We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Rocket Pharmaceuticals Inc (RCKT) COM USD0.01

Sell:$24.00 Buy:$34.98 Change: $1.46 (5.81%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $1.46 (5.81%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $1.46 (5.81%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Rocket Pharmaceuticals, Inc. is a clinical-stage, multi-platform biotechnology company that is focused on the development of gene therapies for rare and devastating diseases. The Company’s clinical-stage ex vivo lentiviral vector (LVV) programs include: Fanconi Anemia (FA), is a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; Leukocyte Adhesion Deficiency-I (LAD-I), is a genetic disorder that causes the immune system to malfunction; Pyruvate Kinase Deficiency (PKD), is a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia, and Infantile Malignant Osteopetrosis (IMO), is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

Contact details

350 5th Ave Ste 7530
United States
+1 (646) 4409100

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.62 billion
Shares in issue:
64.44 million
United States
US dollar

Key personnel

  • Roderick Wong
    Chairman of the Board
  • Kinnari Patel
    President, Chief Operating Officer, Head of Development
  • Gaurav Shah
    Chief Executive Officer, Director
  • Carlos Garciaparada
    Chief Financial Officer, Principal Financial Office
  • Isabel Carmona
    Chief Human Resource Officer, Senior Vice President
  • John Militello
    Principal Accounting Officer, Vice President - Finance, Senior Controller, Treasurer
  • Jonathan Schwartz
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.